Antibiotics have drastically reduced the mortality associated with infectious diseases. Yet, their effectiveness and easy access led to misuse and overuse, prompting bacteria to develop resistance. Currently, antibiotics are usually based on essential bacterial pathways, and therefore cover a broad spectrum of bacteria. There is however a high risk of resistance development, leading to a dramatic health issue and new medicines are thus urgently needed. A major challenge for efficient drug design is to find and characterize the appropriate bacterial targets. We have a new target which is patented and we have hits responsible of its specific inhibition in vitro and in vivo. We want to decipher their mode of action in cristalo, in silico and in vivo, in order to potentiate them into lead molecules, while enlarging the bacterial range to priority pathogens of the ESKAPE group.